- Type
- not stated
- Format
- Multimodal — audio recordings with transcripts (voice-first Dynamic Dialogues), phrase-level annotated marketing text/visual-aid content, and tabular panel survey plus prescribing-outcome records
- Volume
- 20M+ message-benchmark records (stated on the page) plus, at a conservative 30-90 seconds per voice response, roughly 0.5-3M hours of HCP spoken audio with paired transcripts accumulated across the program's life. Basis: the 20M+ figure is the vendor's own benchmark count; audio volume derived from the voice-first modality applied to a fraction of those interactions.
- Users
- ~15,000-60,000 HCP panel members plus several thousand pharma client end-users. Basis: an in-house HCP panel described as 'deep, proprietary' supporting 20M+ benchmark records; a panel large enough to sustain that volume across repeated 2-7 day recall cycles implies tens of thousands of consenting prescribers.
- History
- 11 years
- Update frequency
- not stated
- Growth
- Active — the offering is positioned around a current AI engine (Sagan) with three shipping capabilities and claimed 93% predictive accuracy, and the corporate record shows a subsequent combination/M&A event in its funding history, indicating an expanding rather than run-off business. ~550 employees supports active delivery capacity.
- Launched
- ~2013-2016 for ZoomRx as a life-sciences analytics firm; PET as an AI-engineered product is materially newer (~2022-2024, inferred from the Sagan AI engine branding and the voice-first capability wave that followed general-purpose speech models becoming deployable).
- Delivery
- not stated
- Entity mapping
- not stated
- Sample
- not stated
- Point-in-time
- not stated
- Licence
- not stated